Effectiveness of β-adrenergic blockers in coronary heart disease
A number of studies have demonstrated the effectiveness of β-AB in reducing mortality with long-term use after myocardial infarction (MI); according to meta-analysis, this reduction is 23%. Long-term use of beta-blockers also reduces the risk of repeated cardiovascular events (SSSob).
A comparison of cross-sectional studies showed that the higher the β-blockade level (decrease in heart rate compared with the control group), the greater the benefit, β-blockade after myocardial infarction (MI) and in CHF is extremely cost-effective.
According to the Coronary Heart Disease Policy Model, the use of β-AB during the year by all patients after the first MI will prevent 62 thousand of MI and reduce by 72 thousand the number of deaths from coronary heart disease (KBS) within 20 years. The ratio of cost-effectiveness of β-AB therapy is <$ 11 thousand for QALY.
Beta-blockers such as carvedilol and metoprolol reduce mortality in patients with chronic heart failure (CHF).